| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
AG01 (0-300 µg/mL, 48-72 hours) can inhibit the proliferation of MDA-MB-231 and HS578-T cells and reduce the number of Ki67 positive cell nuclei[1]. AG01 (0-100 µg/mL, 5 hours) can inhibit the migration and invasion of MDA-MB-231 and HS578-T cells[1]. AG01 (100 µg/mL, 24-72 hours) can reduce the phosphorylation status of AKt, Src, and Erk1/2 in MDA-MB-231 and HS578-T cells[1]. AG01 (100 µg/mL, 24-72 hours) can reduce the expression of Axl, c-MET, ICAM-1, MMP-2, SNAIL, HIF-1α, VEGF, endogenous progranulin, SPARC, and cell adhesion and migration protein fibronectin in MDA-MB-231 and HS578-T cells [1].
|
|---|---|
| ln Vivo |
AG01 (10 mg/kg, intraperitoneal injection, twice a week for 40 days) inhibited tumor growth and Ki67 expression in a mouse MDA-MB-231 xenograft nude model [1].
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: MDA-MB-231, HS578-T cells Tested Concentrations: 0, 25, 50, 100, 200, 300 µg/mL Incubation Duration: 48, 72 h Experimental Results: Inhibited cells proliferation, resulted in a dose-dependent inhibition of MDA-MB-231 and HS578-T cells proliferation by 44% and 51% at 300 µg/mL compared with control. Cell Migration Assay [1] Cell Types: MDA-MB-231, HS578-T cells Tested Concentrations: 25, 50, 100 µg/mL Incubation Duration: 5 h Experimental Results: Inhibited cells migration in a dose-dependent, with the highest reduction of 78.2%, 77.5% at 100 µg/mL for MDA-MB-231, HS578-T cells. Western Blot Analysis[1] Cell Types: MDA-MB-231, HS578-T cells Tested Concentrations: 100 µg/mL Incubation Duration: 24, 48, 72 h Experimental Results: Decreased the phosphorylation status of Akt (14.8%), Src (23.6%), and Erk1/2 (20.3%) at 24 h and decreased phosphorylation of Akt (63%), Src (55.4%), and Erk1/2 (55.2%) at 72 h compared to control, decreased the ratio of phosphorylated protein to its total corresponding protein expression for Akt (71.9%), Src (49.8%), and Erk1/2 (62%) at 72 h in MDA-MB-231 cells. Decreased the phosphorylation status of Akt (44.5%), Src (31.5%), and ERK1/2 (35.5%) at 24 h while decreased FAK phosphorylation (44.5%) at 48 h, decreased the ratio of phosphorylated protein to its total corresponding protein expression for p-Src/Src (44.3%), p-Akt/Akt (47.3%), and p-ERK1/2/ERK (46%) at 48 h in HS578-T cells. Reduced c-MET expression of 59.7%. Reduced SNAIL expression of 23.3% and 89%, ICAM-1 of 93.8% and 33.8%, AXL of 13.2% and 33.4% in MDA-MB-231 and HS578-T cells, respectively, reduced endogenous progranulin level in time-dependent reduction with MDA-MB-231 showing 37.7% reduction by 72 h and HS578-T showing almost a 100% reduction by 48 h. Reduced cell adhesion and migratory protein-fbronectin in time-dependent decrease of 25.4% at 72 h as compared to its control lysate in MDA-MB-231 cells. |
| Animal Protocol |
Animal/Disease Models: MDA-MB-231 (1.5x106) xenograft nude mice (6-8-week-old, female) model[1]
Doses: 10 mg/kg Route of Administration: i.p., twice weekly, 40 days Experimental Results: Reduced Vt/V0 ratio and tumor weights by 50% compared to control human IgG treated group, reduced Ki67 expression in tumor sections by 52.5% compared to control groups, showed a 50% reduction of the mitotic index compared to control and 65% reduction of relative microvessel numbers compared to control HuIgG-treated animals. |
| References |
| Appearance |
Typically exists as solids at room temperature
|
|---|---|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
